Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

The role of contrast-enhanced ultrasound in the diagnosis of malignant non-mass breast lesions and exploration of diagnostic criteria.

Tytuł:
The role of contrast-enhanced ultrasound in the diagnosis of malignant non-mass breast lesions and exploration of diagnostic criteria.
Autorzy:
Zhang F; Department of Ultrasound, Shanghai General Hospital of Nanjing Medical University, Shanghai, China.; Department of Ultrasound, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jin L; Department of Ultrasound, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Li G; Department of Ultrasound, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jia C; Department of Ultrasound, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shi Q; Department of Ultrasound, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Du L; Department of Ultrasound, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Wu R; Department of Ultrasound, Shanghai General Hospital of Nanjing Medical University, Shanghai, China.; Department of Ultrasound, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Źródło:
The British journal of radiology [Br J Radiol] 2021 Apr 01; Vol. 94 (1120), pp. 20200880. Date of Electronic Publication: 2021 Feb 09.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: London, British Institute of Radiology.
MeSH Terms:
Contrast Media*
Breast Neoplasms/*diagnostic imaging
Image Enhancement/*methods
Ultrasonography, Mammary/*methods
Adult ; Aged ; Aged, 80 and over ; Breast/diagnostic imaging ; Female ; Humans ; Middle Aged ; Reproducibility of Results ; Retrospective Studies ; Sensitivity and Specificity ; Young Adult
References:
J Ultrasound Med. 2019 Sep;38(9):2259-2273. (PMID: 30597640)
Acta Radiol Open. 2018 May 29;7(6):2058460118774957. (PMID: 29872548)
Clin Hemorheol Microcirc. 2019;72(3):293-303. (PMID: 30856103)
AJR Am J Roentgenol. 2012 Aug;199(2):292-9. (PMID: 22826389)
Ultrasound Med Biol. 2017 Nov;43(11):2582-2590. (PMID: 28844465)
Biomed Res Int. 2014;2014:572532. (PMID: 24967380)
J Ultrasound Med. 2009 Jul;28(7):911-20. (PMID: 19546333)
Med Phys. 2003 Nov;30(11):2919-26. (PMID: 14655939)
Radiology. 2007 Sep;244(3):718-26. (PMID: 17690324)
Zhonghua Zhong Liu Za Zhi. 2011 Jun;33(6):465-9. (PMID: 21875490)
World J Clin Cases. 2020 Feb 26;8(4):700-712. (PMID: 32149054)
Radiology. 2010 Oct;257(1):24-39. (PMID: 20851938)
Eur J Radiol. 2012 Apr;81(4):e444-50. (PMID: 21612882)
Eur J Radiol. 2015 Jan;84(1):77-85. (PMID: 25455412)
Diagn Interv Radiol. 2015 May-Jun;21(3):189-94. (PMID: 25835079)
Eur J Radiol. 2016 Jan;85(1):48-54. (PMID: 26724648)
J Ultrasound Med. 2014 Mar;33(3):421-30. (PMID: 24567453)
Breast Cancer. 2007;14(4):371-80. (PMID: 17986802)
Eur Radiol. 2016 Oct;26(10):3542-9. (PMID: 26787603)
Radiographics. 2013 Jan-Feb;33(1):213-28. (PMID: 23322838)
Ultrasound Med Biol. 2017 Jan;43(1):83-90. (PMID: 27717515)
Onco Targets Ther. 2017 Feb 22;10:1123-1129. (PMID: 28260926)
Gland Surg. 2019 Jun;8(3):258-270. (PMID: 31328105)
Ultrasound Med Biol. 1990;16(6):553-9. (PMID: 2238263)
Asian Pac J Cancer Prev. 2014;15(19):8149-53. (PMID: 25338998)
J Ultrasound Med. 2008 Jun;27(6):821-31. (PMID: 18499842)
Neoplasma. 2018;65(1):124-131. (PMID: 29322796)
J Clin Oncol. 2005 Mar 10;23(8):1782-90. (PMID: 15755986)
Acta Radiol. 2017 Sep;58(9):1054-1060. (PMID: 28114809)
Ultrasound Med Biol. 2018 Aug;44(8):1703-1711. (PMID: 29861297)
Hum Pathol. 2002 Sep;33(9):863-70. (PMID: 12378509)
Radiol Med. 2015 Oct;120(10):905-10. (PMID: 25725790)
Breast Cancer. 2012 Oct;19(4):295-301. (PMID: 22456924)
Substance Nomenclature:
0 (Contrast Media)
Entry Date(s):
Date Created: 20210209 Date Completed: 20210330 Latest Revision: 20220421
Update Code:
20240104
PubMed Central ID:
PMC8010562
DOI:
10.1259/bjr.20200880
PMID:
33560894
Czasopismo naukowe
Objectives: To assess the value of contrast-enhanced ultrasound (CEUS) for diagnosing malignant non-mass breast lesions (NMLs) and to explore the CEUS diagnostic criteria.
Methods: A total of 116 patients with 119 NMLs detected by conventional US were enrolled. Histopathological results were used as the reference standard. The enhancement characteristics of NMLs in CEUS were compared between malignant and benign NMLs. The CEUS diagnostic criteria for malignant NMLs were established using independent diagnostic indicators identified by binary logistic regression analysis. The diagnostic performance of Breast Imaging Reporting and Data System-US (BI-RADS-US), CEUS, and BI-RADS-US combined with CEUS was evaluated and compared.
Results: Histopathological results showed 63 and 56 benign and malignant NMLs. Enhancement degree (OR = 5.75, p = 0.003), enhancement area (OR = 4.25, p = 0.005), and radial or penetrating vessels (OR = 7.54, p = 0.003) were independent diagnostic indicators included to establish the CEUS diagnostic criteria. The sensitivity and specificity of BI-RADS-US, CEUS, and BI-RADS-US combined with CEUS were 100 and 30.2%, 80.4 and 74.6%, and 94.6 and 77.8%, respectively; the corresponding areas under the receiver operating characteristic curve (AUC) were 0.819, 0.775, and 0.885, respectively.
Conclusions: CEUS has a high specificity in malignant NML diagnosis based on the diagnostic criteria including enhancement degree, enhancement area, and radial or penetrating vessels, but with lower sensitivity than BI-RADS-US. The combination of CEUS and BI-RADS-US is an effective diagnostic tool with both high sensitivity and specificity for the diagnosis of malignant NMLs.
Advances in Knowledge: In this study, we assessed the diagnostic value of CEUS for malignant NMLs and constructed a feasible diagnostic criterion. We further revealed that the combination of CEUS and BI-RADS-US has a high diagnostic value for malignant NMLs.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies